Altos Biologics submits EMA Marketing Authorisation Application for aflibercept biosimilar ALT-L9

News
Article

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

An eye surrounded by digital interfaces and LEDs. AI generated. Image credit: ©aicandy – stock.adobe.com

The Phase III clinical trial for ALT-L9 began in 2022 and incorporated over 400 participants from 12 countries. Image credit: ©aicandy – stock.adobe.com

Altos Biologics Inc. has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) for ALT-L9, an aflibercept biosimilar. This biosimilar was developed by Alteogen Inc.; Altos Biologics Inc. is a subsidiary of Alteogen.1

According to the press release from Alteogen1, the Phase III clinical trial for ALT-L9 began with initial clinical trial approval in 2022 and incorporated over 400 participants from 12 countries, including those in Europe, South Korea and Japan. The study compared efficacy, safety, and immunogenicity against aflibercept (Eylea) in the indication of wet age-related macular degeneration(AMD). The primary endpoint of the study was change in best-corrected visual acuity (BCVA) over 8 weeks.

Dr Hyi Jeong Ji, Chief Executive Officer of Altos Biologics, shared the further plans for this biosimilar in the release1, saying, "Following the European Marketing Authorization Application for ALT-L9, we plan to pursue product approvals in target markets including Korea."

Altos Biologics expects to receive approval from EMA by 2025, aligned with the substance patent expiration, and intends to negotiate License Agreements with potential distributors worldwide.1 In the press release, the company also expressed an intent to leverage expertise gained from this trial to develop "a novel multi-specific fusion protein therapeutic incorporating Tie2 regulators, in addition to anti-VEGF mechanisms similar to aflibercept, aimed at stabilising blood vessels."

Reference:

1. Altos Biologics Files Approval of Aflibercept Biosimilar. Alteogen Inc. Published July 1, 2024. Accessed July 2, 2024. https://www.morningstar.com/news/pr-newswire/20240701cn52238/altos-biologics-files-approval-of-aflibercept-biosimilar

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.